公司資料
FEMASYS 股價、新聞與催化劑
- 股票代碼:
- FEMY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.10 USD (-2.78%)
收盤價
最後更新: 2026年10月1日
22.4M USD
市值
股價為何變動
截至 2026年10月1日，FEMY 下跌 2.78%，收於 $2.10。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Women's Health Medical Device Company
Femasys develops office-based products for reproductive health. Its portfolio addresses permanent contraception, infertility treatment, and diagnostic evaluation of the uterus and fallopian tubes.
FemBloc Permanent Contraception
FemBloc is a non-surgical permanent birth-control system delivered through the fallopian tubes in a physician's office. The product is designed to avoid surgical incisions, general anesthesia, and implanted metal devices.
FINALE Pivotal Program
The FINALE study is the final stage of the U.S. pivotal clinical program for FemBloc. The trial is intended to provide the effectiveness and safety evidence needed for a future FDA submission.
FemaSeed Fertility Treatment
FemaSeed delivers sperm directly into a selected fallopian tube, closer to the site of fertilization than standard intrauterine insemination. It is positioned as an office-based option before more invasive assisted-reproduction procedures.
Diagnostic Product Portfolio
FemVue and FemCath products help physicians evaluate fallopian-tube patency and the uterine cavity. These commercial devices provide an established channel with obstetricians, gynecologists, and fertility specialists.
未來催化劑
- Completion of the pivotal FINALE study of FemBloc to support a future U.S. regulatory submission.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。